PTC (NASDAQ: PTC) today announced advancements to its application lifecycle management (ALM) portfolio with the release of ...

PTC (PTC) is drawing investor attention after a recent stretch of weaker share performance, with the stock showing declines ...

PTC (NASDAQ: PTC) will release its fiscal 2026 first quarter and on Wednesday, February 4 th after the stock market closes.

Conference draws participants from more than 60 countries; demand for leadership programs reaches capacity From sold ...

Shares of PTC Therapeutics jumped 15% on Jan. 8 to $20.65, after the maker of Duchenne muscular dystrophy drug Emflaza told investors it expected its revenues to rise 135% year over year for 2017 and ...

PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...

PTC Therapeutics (PTCT) beats 2025 revenue guidance, details Evrysdi royalties and Sephience growth, and sets 2026 outlook.

Welcoming back in-person delegates to its LiveWorx conference for the first time since the pre-pandemic days of 2019, and noting that the company finds itself in one of the greatest periods of change ...

Shares of PTC Inc. PTC shed 1.18% to $171.52 Friday, on what proved to be an all-around great trading session for the stock ...

Four months after Europe's drug reviewers doubled down and recommended the withdrawal of PTC Therapeutics' Translarna for lack of efficacy, the drug's regulatory odyssey is taking yet another turn.